HC Wainwright & Co. Reiterates Buy on ADMA Biologics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on ADMA Biologics (NASDAQ:ADMA) and maintained a price target of $5.
November 17, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst reaffirms a Buy rating on ADMA Biologics and maintains a $5 price target, potentially influencing investor confidence and stock price.
The reiteration of a Buy rating and maintenance of a price target by a reputable analyst can lead to increased investor confidence and a positive short term impact on ADMA Biologics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100